Abstract

Introduction: The combination of fluticasone (FLUT) and formoterol (FORM) in a single inhaler (FLUT/FORM; flutiform®) is approved for the maintenance treatment of asthma. This analysis assessed the efficacy of FLUT/FORM versus FLUT in patients who had previously received ICS therapy.

Results: FLUT/FORM significantly (p<0.05) improved lung function measures and increased the percentage of asthma control days (no symptoms, no rescue medication use and no sleep disturbance due to asthma) compared with FLUT (Table). The incidence and annualized rate of any exacerbation was significantly lower with FLUT/FORM.

Conclusions: FLUT/FORM significantly improves lung function and asthma control measures, and is associated with a lower incidence of exacerbations compared with FLUT.